atorvastatin has been researched along with Kidney Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Finlay, GA; Kwiatkowski, DJ; Malhowski, AJ; Malinowska-Kolodziej, I; Polizzi, K | 1 |
| Haygood, TM; Jonasch, E; Manoukian, GE; Qiao, W; Tannir, NM; Tu, SM | 1 |
1 trial(s) available for atorvastatin and Kidney Neoplasms
| Article | Year |
|---|---|
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Zoledronic Acid | 2011 |
2 other study(ies) available for atorvastatin and Kidney Neoplasms
| Article | Year |
|---|---|
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Atorvastatin; Cholesterol; Cystadenoma; Disease Models, Animal; Female; Hemangioma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Survival Rate; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2009 |